CC
JAZZ icon

Centiva Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Centiva Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,632
Closed -$1.3M – 2030
2024
Q3 		$1.3M Sell
11,632
-12,887
-53% -$1.41M 0.03% 701
2024
Q2 		$2.62M Buy
24,519
+20,649
+534% +$2.27M 0.04% 294
2024
Q1 		$466K Sell
3,870
-274
-7% -$33.6K 0.01% 1027
2023
Q4 		$510K Sell
4,144
-2,849
-41% -$356K 0.01% 949
2023
Q3 		$905K Buy
6,993
+2,552
+57% +$340K 0.02% 689
2023
Q2 		$551K Buy
4,441
+2,888
+186% +$389K 0.01% 782
2023
Q1 		$227K Buy
+1,553
New +$230K 0.01% 1175
2022
Q4 		– Sell
-3,272
Closed -$436K – 1500
2022
Q3 		$436K Buy
+3,272
New +$498K 0.01% 921
2021
Q3 		– Sell
-1,289
Closed -$229K – 1451
2021
Q2 		$229K Buy
+1,289
New +$223K 0.01% 1163
2020
Q2 		– Sell
-9,160
Closed -$914K – 741
2020
Q1 		$914K Buy
+9,160
New +$1.18M 0.04% 212

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Centiva Capital's JAZZ Position: Q4 2024 in Review

Centiva Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 11,632 shares — an estimated $1.3M sold.

Centiva Capital first reported a position in JAZZ in Q1 2020 and held it in 10 quarters. The position peaked at $2.62M in Q2 2024. 509 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • Centiva Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 11,632 Jazz Pharmaceuticals shares in Q4 2024, an estimated $1.3M.
  • Centiva Capital first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 10 quarters.
  • Centiva Capital's Jazz Pharmaceuticals position peaked at $2.62M in Q2 2024.
  • 509 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.